Niagen Bioscience, Inc. current report, 08 March 2023

SEC Filing Summary: ChromaDex Corporation (CDXC)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on March 8, 2023. The filing serves to announce the Company's financial results for the fourth quarter and the full year ended December 31, 2022. The report also references a corporate presentation released on the same date.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are attached to the filing but not included in the text of this summary.

Material Changes

The filing text does not provide specific data regarding material changes versus prior periods. It only confirms that results for the fourth quarter and full year 2022 have been announced.

Guidance, Outlook, and Risks

The filing includes a Regulation FD disclosure regarding a corporate presentation made available on the Company's website. No specific guidance, outlook, management commentary, risks, or unusual items are detailed within the text of this Form 8-K.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2022 financial figures.
  • Examine Exhibit 99.2 (Investor Presentation) for management commentary, strategic outlook, and risk factors.
  • Verify the Company's liquidity position and debt obligations in the full financial statements referenced in the exhibits.
  • Confirm any forward-looking statements or guidance provided in the attached presentation materials.